Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Purchased by Barclays PLC

Barclays PLC boosted its position in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) by 21.5% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 70,167 shares of the company’s stock after buying an additional 12,418 shares during the quarter. Barclays PLC owned approximately 0.16% of Kyverna Therapeutics worth $343,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Deerfield Management Company L.P. Series C boosted its stake in shares of Kyverna Therapeutics by 35.6% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 1,983,000 shares of the company’s stock worth $14,872,000 after acquiring an additional 520,663 shares in the last quarter. Novo Holdings A S raised its holdings in Kyverna Therapeutics by 5.7% in the 3rd quarter. Novo Holdings A S now owns 1,850,000 shares of the company’s stock worth $9,046,000 after purchasing an additional 100,000 shares during the period. Millennium Management LLC boosted its position in Kyverna Therapeutics by 32.8% during the second quarter. Millennium Management LLC now owns 923,082 shares of the company’s stock worth $6,923,000 after purchasing an additional 227,988 shares in the last quarter. Great Point Partners LLC grew its holdings in Kyverna Therapeutics by 232.8% in the second quarter. Great Point Partners LLC now owns 499,152 shares of the company’s stock valued at $3,744,000 after purchasing an additional 349,152 shares during the period. Finally, Geode Capital Management LLC increased its position in shares of Kyverna Therapeutics by 19.0% in the third quarter. Geode Capital Management LLC now owns 443,312 shares of the company’s stock valued at $2,168,000 after buying an additional 70,714 shares in the last quarter. Hedge funds and other institutional investors own 18.08% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on KYTX. Wells Fargo & Company decreased their target price on Kyverna Therapeutics from $44.00 to $24.00 and set an “overweight” rating on the stock in a research report on Friday, November 15th. RODMAN&RENSHAW upgraded shares of Kyverna Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 9th. UBS Group initiated coverage on shares of Kyverna Therapeutics in a research note on Thursday, October 10th. They set a “buy” rating and a $13.00 target price for the company. HC Wainwright decreased their price target on shares of Kyverna Therapeutics from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 20th. Finally, Rodman & Renshaw initiated coverage on Kyverna Therapeutics in a research note on Wednesday, October 9th. They set a “buy” rating and a $16.00 price objective for the company. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Kyverna Therapeutics presently has an average rating of “Buy” and a consensus price target of $25.71.

Kyverna Therapeutics Price Performance

NASDAQ KYTX opened at $3.33 on Monday. The stock’s fifty day moving average is $4.32 and its two-hundred day moving average is $5.98. Kyverna Therapeutics, Inc. has a fifty-two week low of $3.24 and a fifty-two week high of $35.06.

Kyverna Therapeutics (NASDAQ:KYTX) last released its quarterly earnings data on Wednesday, November 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.81) by $0.01. The firm had revenue of $0.01 million for the quarter. On average, research analysts anticipate that Kyverna Therapeutics, Inc. will post -3.29 earnings per share for the current year.

Kyverna Therapeutics Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.